Last reviewed · How we verify
NCT06742307: Fixed farcimab
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
Phase 4 trial testing Faricimab Injection [Vabysmo] in Macular Degeneration Choroidal Neovascularization in 40 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Hospital Authority, Hong Kong |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 21 August 2025 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 February 2027 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Faricimab Injection [Vabysmo] — full drug profile →
Conditions studied
- Macular Degeneration Choroidal Neovascularization — all drugs for Macular Degeneration Choroidal Neovascularization →
Sponsor
Hospital Authority, Hong Kong
Who can join
50 and older, any sex, with Macular Degeneration Choroidal Neovascularization. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06742307
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Faricimab Injection [Vabysmo]
Trials testing the same drug.
- NCT07367282 — Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration · Phase 4 · not yet recruiting
- NCT07461441 — Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal · Phase 3 · recruiting
- NCT07526857 — Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy · completed
- NCT06890026 — Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration · completed
- NCT06902207 — Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy · completed
Other Hospital Authority, Hong Kong trials
Trials by the same sponsor.
- NCT07058623 — Nurse-Led Telehealth vs In-Person Follow-Up After Total Knee Replacement · NA · recruiting
- NCT07005973 — Effects of Mobile-based Mindfulness Intervention to Reduce Preoperative Anxiety for Patients Undergoing Elective Surgery · NA · recruiting
- NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
- NCT06719024 — Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus · Phase 2, PHASE3 · recruiting
- NCT06559254 — TDCS as Augmentation Therapy to Cognitive Training in Mild Dementia · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06742307 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Authority, Hong Kong
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06742307.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing